BRAF and glioma: In this context, many pediatric gliomas are characterized by hotspot driver mutations (H3.1/H3.3_K27M, H3.3_G34R/V, BRAF_V600E, IDH1_R132H)6 or by single fusion events (ETV6:NTRK3, KIAA1549:BRAF).7,8 This makes them perfect candidates for the use of ctDNA to monitor treatment response enabling early detection of tumor progression over the course of the disease.